RxDoctor Payments Data

Kurt Spriggs, DO

Interventional Cardiology · Grand Junction, CONPI 1851337802

Payments from drug & device makers

$3,093in general payments, 2019–2025

Across 104 payments — averaging $29.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Boston Scientific$618
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$220
  • Philips North America LLC$131
  • Chiesi USA, Inc.$128
  • Impulse Dynamics (USA) Inc.$125
  • plus $475 from 14 others

What the payments were for

  • Travel & lodging$34511%
  • Food & beverage$2,74989%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,093 in reported general payments places this provider in the 25th percentile of 111 interventional cardiology providers in Colorado.

See all interventional cardiology providers in Colorado

Medicare billing

Part B allowed, 2024
$172,562
Medicare patients
892
Services billed
2,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$65,316
XareltoRivaroxaban32$36,941
EntrestoSacubitril/Valsartan31$29,841
BrilintaTicagrelor18$9,535
Metoprolol Succinate100$1,071
Flecainide Acetate14$973
Ezetimibe25$818
Warfarin Sodium88$662
Atorvastatin Calcium100$603
ClopidogrelClopidogrel Bisulfate65$583
Isosorbide Mononitrate ErIsosorbide Mononitrate30$530
Nitroglycerin35$459
Losartan Potassium56$398
Lisinopril34$313
Furosemide47$288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$39$65,31654 claims
Johnson & JohnsonXarelto$54$36,94132 claims
NovartisEntresto$39$29,84131 claims
AstraZenecaBrilinta$13$9,53518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 111 interventional cardiology providers in Colorado.

Other interventional cardiology in Grand Junction

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →